Suraksha Diagnostic Ltd
Suraksha Diagnostic Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Targeting a revenue growth of 15% annually, as confirmed by management. Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management.
From Suraksha Diagnostic Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Targeting a revenue growth of 15% annually, as confirmed by management.
- Volume mix expected to remain stable with around 75% pathology and 25% radiology tests.
- Continued organic expansion with plans to open 12-15 new centers every year for the next 3 years, aiming to reach 100 centers.
- Focus on increasing the number of polyclinic chambers and associated doctor fees, showing improved conversion rates.
- Stable revenue mix between pathology (around 54-56%) and radiology (44-45%), consistent over the last 2-3 years.
- Growth supported by technology investments and operational efficiencies.
2 more points from Suraksha Diagnostic Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Suraksha Diagnostic Limited has budgeted a capital expenditure (capex) of around INR 70 crores per year.
- Of this capex, 5% to 7% is allocated towards maintenance, with the remainder directed towards expansion.
- The company plans to add 12 to 15 new centers annually over the next three years, targeting a total of 100 centers within that period.
- Future capex plans do not include potential mergers and acquisitions (M&A); acquisitions will be additional to the INR 70 crore capex.
- The company is actively exploring strategic partnerships and acquisitions that align with their values to expand geographic footprint and service offerings.
2 more points from Suraksha Diagnostic Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Suraksha Diagnostic Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suraksha Diagnostic Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Suraksha Diagnostic Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q3 FY25 results?
Targeting a revenue growth of 15% annually, as confirmed by management. Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Suraksha Diagnostic Limited has budgeted a capital expenditure (capex) of around INR 70 crores per year.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.